Search

Smith & Nephew PLC

Закрыт

1,263 -1.41

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1258.5

Макс.

1280.5

Ключевые показатели

By Trading Economics

Доход

296M

Продажи

3B

P/E

Средняя по отрасли

30.104

22.135

Прибыль на акцию

0.429

Дивидендная доходность

3

Рентабельность продаж

9.895

Сотрудники

17,000

EBITDA

723M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+18.25% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.00%

4.29%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.9B

12B

Предыдущая цена открытия

1264.41

Предыдущая цена закрытия

1263

Smith & Nephew PLC График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 нояб. 2025 г., 21:34 UTC

Отчет

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 нояб. 2025 г., 23:45 UTC

Обсуждения рынка

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 нояб. 2025 г., 23:42 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 нояб. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 нояб. 2025 г., 23:24 UTC

Отчет

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 нояб. 2025 г., 23:24 UTC

Отчет

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 нояб. 2025 г., 23:23 UTC

Отчет

JBS NV 3Q EPS 52c >JBS

13 нояб. 2025 г., 23:23 UTC

Отчет

JBS NV 3Q Sales $22.6B >JBS

13 нояб. 2025 г., 23:04 UTC

Обсуждения рынка

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 нояб. 2025 г., 22:02 UTC

Отчет

Nu Holdings 3Q Net $783M >NU

13 нояб. 2025 г., 22:01 UTC

Отчет

Nu Holdings 3Q Rev $4.2B >NU

13 нояб. 2025 г., 21:51 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 нояб. 2025 г., 21:50 UTC

Отчет

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 нояб. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 нояб. 2025 г., 21:41 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 нояб. 2025 г., 21:36 UTC

Приобретения, слияния, поглощения

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 нояб. 2025 г., 21:33 UTC

Обсуждения рынка

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 нояб. 2025 г., 21:33 UTC

Отчет

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 нояб. 2025 г., 21:31 UTC

Отчет

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 нояб. 2025 г., 21:25 UTC

Отчет

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 нояб. 2025 г., 21:25 UTC

Отчет

Figure Tech Solutions 3Q EPS 34c >FIGR

13 нояб. 2025 г., 21:23 UTC

Отчет

Intchains Group 3Q Rev $1.3M >ICG

13 нояб. 2025 г., 21:03 UTC

Отчет

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 нояб. 2025 г., 21:02 UTC

Отчет

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 нояб. 2025 г., 21:01 UTC

Отчет

Applied Materials 4Q Rev $6.8B >AMAT

13 нояб. 2025 г., 21:01 UTC

Отчет

Applied Materials 4Q Gross Margin 48.0% >AMAT

Smith & Nephew PLC Прогноз

Целевая цена

By TipRanks

18.25% рост

Прогноз на 12 месяцев

Средняя 1,516 GBX  18.25%

Максимум 1,700 GBX

Минимум 1,300 GBX

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

8 ratings

5

Покупка

3

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat